IMCDIMCD
IMCD logo
Fair Value
€112.5
Share price09 Jul
€94.7815.8% undervalued intrinsic discount
Loading
1Y0.42%
7D7.44%

IMCD: Share Price Pullback Will Offer Attractive Entry As Ratings Improve

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
25 Nov 24
Updated
09 Jul 26
Views
166
Not Invested

Last Update 09 Jul 26

Fair value Increased 4.48%

IMCD: Global Expansion And Dividend Reset Will Support Future Upside

Analysts have modestly lifted the fair value anchor for IMCD, with a price target moving from about €107.68 to €112.50 as they factor in updated assumptions on growth, margins and valuation, alongside mixed recent Street views, including a higher €105 target from Morgan Stanley and a downgrade with a €75 target from JPMorgan.

Analyst Commentary

Recent research on IMCD points to a split view, with some bullish analysts focusing on valuation support and others, including JPMorgan, highlighting earnings risks and less compelling pricing versus peers. This mix of opinions gives you a range of angles to consider when assessing the stock.

Bullish Takeaways

  • Raising the price target to €105 suggests some bullish analysts see IMCD's current valuation as more aligned with their updated assumptions, rather than stretched.
  • The Equal Weight stance implies IMCD is viewed as reasonably positioned within the sector, not requiring a large valuation premium or discount at this stage.
  • Bullish analysts appear comfortable that, even with sector-wide challenges, IMCD can still execute in line with peers, which supports a more neutral to mildly constructive view on the stock.

Bearish Takeaways

  • JPMorgan's downgrade to Underweight with a €75 target reflects concern that IMCD's mid term earnings could fall well below current consensus expectations.
  • Bearish analysts flag both structural and cyclical headwinds, which they believe may limit IMCD's ability to deliver the earnings trajectory that is currently implied by market expectations.
  • Valuation is viewed by JPMorgan as less attractive than many other stocks in its coverage, suggesting limited upside if earnings do not match existing forecasts.
  • The comment that the earnings tailwind from the Middle East conflict may be fading indicates that some recent support to reported results might not be sustainable, adding another layer of caution to the outlook for IMCD.

What’s in the News for IMCD

  • IMCD agreed to acquire 100% of Merit Solution Co., Ltd, a Bangkok-based distributor of additives for the plastics and compounding industry in Thailand, with closing anticipated in the third quarter of 2026, aiming to broaden its solutions offering and portfolio across Thailand and Southeast Asia. (Source: Recent news reports)
  • IMCD is set to expand its presence in advanced materials and compounding sectors in Southeast Asia through the planned Merit Solution acquisition, which is expected to reinforce the company’s role as a key distributor in the region once completed. (Source: Recent news reports)
  • IMCD opened a Food & Nutrition US Technical Hub and a Pharmaceutical Technical Centre in Allendale, New Jersey, adding new labs and facilities focused on formulation work across food, beverage, nutraceutical and pharmaceutical markets in North America. (Source: Recent news reports)
  • The new IMCD Food & Nutrition Hub in New Jersey includes Application and Bakery Labs geared toward concept ideation, prototype development and co-creation of trend-oriented formulations for local customers. (Source: Recent news reports)
  • At the AGM on April 30, 2026, IMCD approved a cash dividend of €1.81 per share, with ex-dividend date on May 5, 2026, record date on May 6, 2026 and payment date on May 8, 2026. (Source: Company key developments)

Valuation Changes for IMCD

  • Fair Value: updated modestly from €107.68 to €112.50, signalling a slightly higher central valuation anchor for IMCD.
  • Discount Rate: adjusted from 6.86% to 7.16%, indicating a small upward shift in the required return used in the valuation work.
  • Revenue Growth: revised from 4.60% to 5.24%, pointing to a slightly higher assumed future € revenue growth rate in the model.
  • Net Profit Margin: moved from 5.25% to 5.36%, reflecting a minor change in expected future € earnings profitability.
  • Future P/E: changed from 26.85x to 27.21x, implying a slightly higher valuation multiple being applied to IMCD's projected earnings.
2 viewsusers have viewed this narrative update

Key Takeaways

  • Expansion into resilient end-markets and digitalization enhances operational efficiency, customer loyalty, and positions IMCD for sustained revenue and margin growth.
  • Differentiated specialty offerings and industry outsourcing trends support long-term growth, while short-term disruptions are expected to ease as integration and diversification efforts bear fruit.
  • Currency volatility, weak organic growth, high acquisition risks, and mounting competitive pressures threaten margins, cash flow, and IMCD's ability to sustain long-term profitability.

Catalysts

About IMCD
    Distributes, markets, and sells specialty chemicals and ingredients in the Netherlands, rest of Europe, the Middle East, Africa, North America, South America, and the Asia-Pacific.
What are the underlying business or industry changes driving this perspective?
  • IMCD's strategic expansion into high-growth and resilient end-markets (pharma, food & nutrition, personal care) through both organic efforts and targeted M&A increases exposure to industries with strong, recurring demand fundamentals-which can support sustainable revenue and margin expansion as macro uncertainty fades.
  • The company's ongoing investment in digitalization (e.g. sales assistant tool, omnichannel strategy) is expected to drive greater operational efficiency, customer stickiness, and scalability, potentially leading to improved cost structure and higher net margins over the medium to long term.
  • Increased focus by manufacturers on outsourcing sales, marketing, and distribution functions continues to favor specialized third-party distributors like IMCD, which supports long-term revenue growth as industry outsourcing trends deepen.
  • Heightened customer and regulatory demands for innovation, sustainability, and technical expertise position IMCD's differentiated specialty portfolio as a key supplier across industries adopting greener, more complex formulations; this should underwrite above-market growth and gross margin resilience.
  • Recent customer order delays, elevated inventories, and FX headwinds have temporarily dampened reported results and cash flow, but the underlying market share gains, geographic diversification, and multi-region M&A integration efforts set the stage for strong earnings rebound and cash generation as short-term disruptions normalize.
IMCD Earnings and Revenue Growth

IMCD Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming IMCD's revenue will grow by 5.2% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 4.5% today to 5.4% in 3 years time.
  • Analysts expect earnings to reach €300.2 million (and earnings per share of €4.99) by about July 2029, up from €217.6 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as €361.1 million.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 27.2x on those 2029 earnings, up from 22.6x today. This future PE is greater than the current PE for the GB Trade Distributors industry at 22.6x.
  • Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 7.16%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • Volatile foreign exchange rates, particularly the weakening of the U.S. dollar and Indian rupee, have negatively impacted revenue and EBITDA, with management indicating continuing currency headwinds could further suppress reported financials and profit margins.
  • Persistent macroeconomic uncertainty and tariff-related disruptions are leading IMCD's customers to delay orders and refrain from commitments, resulting in elevated inventory, increased working capital requirements, and risk to near-term and potentially longer-term revenue recognition and cash flow.
  • Organic revenue and EBITA growth are modest, with recent quarters showing flat or declining trends; inflation-driven cost increases, especially in personnel, are outpacing organic growth and causing conversion margins and net profits to decline, highlighting difficulty in offsetting fixed cost growth without stronger demand recovery.
  • Heightened M&A pace and reliance on acquisitions for growth expose IMCD to risks of overpaying for targets and integration challenges, as shown by rising amortization and financing costs linked to acquisition-related intangibles and deferred considerations, which could weigh on net margins and cash generation.
  • Increased competition from local players in regions like China, as well as pricing pressures in more commoditized segments, could reduce IMCD's pricing power and market share, contributing to long-term gross margin compression and risking a structural shift in profitability if these trends persist.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of €112.5 for IMCD based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €150.0, and the most bearish reporting a price target of just €75.0.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be €5.6 billion, earnings will come to €300.2 million, and it would be trading on a PE ratio of 27.2x, assuming you use a discount rate of 7.2%.
  • Given the current share price of €83.2, the analyst price target of €112.5 is 26.0% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on IMCD?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

Fair Value vs Share Price

€112.5
vs €94.7815.8% undervalued intrinsic discount
PastFuture06b2015201820212024202620272029Revenue €5.6bEarnings €300.2m
5.2%
Revenue growth
5.4%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on IMCD

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Adequate balance sheet average dividend payer.

Market cap€5.6b
PB2.6x
Estimated Growth4.8%
Dividend Yield1.9%
Full analysis

CEO & management

Marcus Jordan
CEO
2.0yrs
CEO Tenure

Distributes, markets, and sells specialty chemicals and ingredients in the Netherlands, rest of Europe, the Middle East, Africa, North America, South America, and the Asia-Pacific.